2 results
Approved WMOWill not start
The objective of this post market surveillance registry is to assess whether the Imagio OA/US technology for the indication of breast mass/focal finding diagnosis provides performance characteristics that could be used for worldwide clinical…
Approved WMOCompleted
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…